Oragenics, Inc. OGEN 深 沪
等待开盘 04-02 09:30:00 美东时间
0.56
0.000
-0.02%
华盛通- 最 高0.578
- 今 开0.5688
- 成交量 5.71万股
- 最 低 0.5565
- 昨 收 0.5601
- 总市值 242.82万
- 52周最高 7.60
- 市盈率 静 --
- 换手率 1.32%
- 52周最低 0.5038
- 委 比 0.00%
- 总股本 433.60万
- 历史最高 83700.00
- 量 比 0.45
- 振 幅 3.84%
- 历史最低 0.5038
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oragenics Sets New 2025 Annual Shareholder Meeting Date
The latest update is out from Oragenics ( ($OGEN) ). On March 27, 2026, Orageni...
04-01 07:45
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Oragenics, Inc. announced that its audited consolidated financial statements for the year ended December 31, 2025, include an unqualified audit opinion with a going concern explanatory paragraph. The Annual Report on Form 10-K, filed on March 16, 2026, is available on the SEC's EDGAR system and the company's investor relations website. The company specializes in brain-targeted therapeutics via proprietary intranasal delivery technology, focusing ...
03-25 22:30
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Oragenics, Inc. reported significant progress in 2025, transitioning to a focused biotech company with key milestones including NYSE compliance, clinical trial advancements, manufacturing shift to the U.S., and AI partnerships. The company raised $16.5 million, repaid debt, and reduced expenses. In early 2026, they secured ethics approval, initiated trial sites, and prepared for U.S. clinical activities. Priorities for 2026 include completing Pha...
03-17 12:30
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Oragenics, Inc. has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia. The trial aims to evaluate the safety and efficacy of ONP-002, a first-in-class intranasal neurosteroid, in patients with acute concussion and mild traumatic brain injury (mTBI). The first of three planned trial sites is fully operational, with the remaining two sites expected to complete their final regulatory reviews soo...
03-12 12:30
Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has received final Human
03-10 20:33
Oragenics receives Australia HREC approval to start ONP-002 Phase IIa concussion trial
Oragenics receives Australia HREC approval to start ONP-002 Phase IIa concussion trial Oragenics said it received final Human Research Ethics Committee (HREC) approval in Australia to begin a Phase IIa trial of ONP-002 for concussion and mild traumatic brain injury. The company said all required reg
03-10 20:30
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Oragenics, Inc. has received final Human Research Ethics Committee (HREC) approval in Australia to commence its Phase IIa clinical trial for ONP-002, a potential first-in-class pharmacological treatment for mild traumatic brain injury (mTBI). The trial will enroll 40 patients across three Australian sites, with dosing expected to begin by March 2026. ONP-002 targets the underlying biology of mTBI, aiming to reduce neuroinflammation and oxidative ...
03-10 12:30
Oragenics Previews 2026 Milestones; Outlines Clinical And Growth Catalysts For ONP-002 In Concussion And mTBI
Oragenics, Inc. (NYSE:OGEN) ("the "Company") a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today previewed its targeted milestones for
02-09 21:38
Oragenics erhält regulatorische Genehmigung für Phase-2a-Studie in Australien
Oragenics erhält regulatorische Genehmigung für Phase-2a-Studie in Australien Oragenics Inc. hat die erforderlichen regulatorischen und ethischen Genehmigungen eingereicht, um mit der Phase-2-Studie ihres Wirkstoffkandidaten ONP-002 zur Behandlung von Gehirnerschütterungen und leichten traumatischen
02-09 21:30
Oragenics Receives Regulatory and Ethics Approvals for Phase 2 Clinical Trial of ONP-002 in Australia
Oragenics Receives Regulatory and Ethics Approvals for Phase 2 Clinical Trial of ONP-002 in Australia Oragenics Inc. has submitted the required regulatory and ethics approvals to proceed with its Phase 2 clinical trial of ONP-002, a novel intranasal neurosteroid for concussion and mild traumatic bra
02-09 21:30
